Publications


Radiation therapy utilization and outcomes for older women with breast cancer: Impact of molecular subtype and tumor grade;
Haque, W, Kee Yuan, DM, Verma, V, Butler, EB, Teh, BS, Wiederhold, L & Hatch, S 2017, Breast, vol 35, pp. 34-41. DOI:

Ssb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stress;
Shi, W, Vu, T, Boucher, D, Biernacka, A, Nde, J, Pandita, RK, Straube, J, Boyle, GM, Al-Ejeh, F, Nag, P, Jeffery, J, Harris, JL, Bain, AL, Grzelak, M, Skrzypczak, M, Mitra, A, Dojer, N, Crosetto, N, Cloonan, N, Becherel, OJ, Finnie, J, Skaar, JR, Walkley, CR, Pandita, TK, Rowicka, M, Ginalski, K, Lane, SW & Khanna, KK 2017, Blood, vol 129, no. 18, pp. 2479-2492. DOI:

Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff;
Bhattacharyya, A, Jain, N, Prasad, S, Jain, S, Yadav, V, Ghosh, S & Sengupta, S 2017, BMC Dermatology, vol 17, no. 1, 5. DOI:

Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff;
Bhattacharyya, A, Jain, N, Prasad, S, Jain, S, Yadav, V, Ghosh, S & Sengupta, S 2017, BMC Dermatology, vol 17, no. 1, 5. DOI:

Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff;
Bhattacharyya, A, Jain, N, Prasad, S, Jain, S, Yadav, V, Ghosh, S & Sengupta, S 2017, BMC Dermatology, vol 17, no. 1, 5. DOI:

Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff;
Bhattacharyya, A, Jain, N, Prasad, S, Jain, S, Yadav, V, Ghosh, S & Sengupta, S 2017, BMC Dermatology, vol 17, no. 1, 5. DOI:

Characterization of ventral incisional hernia and repair using shear wave elastography;
Chaudhry, A, Fernandez-Moure, JS, Shajudeen, PS, Van Eps, JL, Cabrera, FJ, Weiner, BK, Dunkin, BJ, Tasciotti, E & Righetti, R 2017, Journal of Surgical Research, vol 210, pp. 244-252. DOI:

Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis;
Valerio, DG, Xu, H, Chen, C-W, Hoshii, T, Eisold, ME, Delaney, C, Cusan, M, Deshpande, AJ, Huang, C-H, Lujambio, A, Zheng, YG, Zuber, J, Pandita, TK, Lowe, SW & Armstrong, SA 2017, Cancer Research, vol 77, no. 7, pp. 1753-1762. DOI: